Nicholas J. Vogelzang, MD, discusses some of the approvals and different regimens seen in today’s renal cell carcinoma treatment landscape.
Nicholas J. Vogelzang, MD, the chairman of medical oncology at Comprehensive Cancer Centers and a clinical professor of medicine at University of Nevada, Reno School of Medicine and University of Nevada, Las Vegas School of Medicine, discusses some of the approvals and different regimens seen in today’s renal cell carcinoma (RCC) treatment landscape.
The treatment landscape for RCC has significantly grown over the past decade, specifically in the frontline setting, due to several new combinations becoming available for patients with clear cell histology.
Vogelzang maps out the timeline of the many approvals that have changed the way patients with RCC are treated including nivolumab (Opdivo)/ipilimumab (Yervoy), pembrolizumab (Keytruda), axitinib (Inlyta), and more.
Transcription:
0:08 | The landscape is confusing to everyone, including treating doctors. The longest approval has been nivolumab/ipilimumab. Those data with Dr. Motzer have been available for about 5 years, so we’ve gotten used to using nivolumab/ipilimumab. That was approved for poor- or intermediate-risk disease and had the best benefit in patients with sarcomatoid histology. It left good-risk patients more or less out of the picture.
0:56 | Then we got approval for pembrolizumab and axitinib, and a lot of doctors liked pembrolizumab/axitinib because it covered good-risk [patients] and we had both a phase 2 and a phase 3 [trial as evidence]. A lot of doctors got comfortable with pembrolizumab and axitinib. Then we had, if you will, the not very positive study of avelumab and axitinib and that did not reach a survival end point compared with sunitinib [Sutent].
1:41 | Then this year, we got the nivolumab/cabozantinib and the CLEAR study of lenvatinib and pembrolizumab. And then lastly, of course, we still have the cabozantinib monotherapy approved as first line for patients.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More